Bexsero contains different proteins taken from group B Neisseria meningitidis bacteria. The combination of proteins was chosen to protect against the majority of MenB strains. They are also expected to protect against other types of meningococcal bacteria, including MenW.
Apart from these active ingredients, the vaccine contains very small amounts of these ingredients:
- Aluminium which strengthens and lengthens the immune response to the vaccine
- salt (sodium chloride)
- sugar (sucrose) and an amino acid called histidine, both used as acidity regulators
Bexsero is an FDA-approved vaccine to prevent invasive disease caused by Neisseria meningitidis serogroup B.
Bexsero was approved for use in 2014 for individuals 10 through 25 years of age.
Bexsero is for intramuscular use only.
The 2 doses of Bexsero can be completed in 1 month.
The meningitis vaccine most people may have received when they were younger covered meningitis ACWY, but not meningitis B.